23 June 2017 - Maviret and Vosevi evaluated under accelerated assessment.

The EMA has recommended granting marketing authorisations in the European Union for Maviret and Vosevi, two new medicines indicated for the treatment of chronic hepatitis C virus infection in adults.

Both Maviret and Vosevi are active against all genotypes of the virus and, with some differences between the two medicines, may be specifically useful in some patients who failed or cannot use previously available therapies. As this is considered to be of major public health interest in terms of therapeutic innovation, both medicines were evaluated under the EU’s accelerated assessment mechanism, which aims to speed up patients’ access to new medicines where there is an unmet medical need.

Read EMA press release